This workshop examines the emerging complexity of dual- and multi-payload ADC design, where the promise of enhanced efficacy through mechanistic synergy must be balanced against fundamental constraints in biology, chemistry, and translational predictability. It asks whether combining payloads truly expands the therapeutic window or whether it introduces new layers of variability in exposure, toxicity, and resistance evolution.

• Explore how dual and multi payload ADCs are enabling synergistic mechanisms that outperform traditional combination approaches
• Understand how rational payload pairing strategies can expand addressable patient populations and overcome emerging resistance mechanisms
• Examine the chemistry and translational challenges associated with linker payload synthesis, in vivo evaluation, and optimization of dual payload systems
• Learn how developers are integrating novel payload classes alongside established cytotoxics to revive promising mechanisms and differentiate next generation ADCs
• Assess evolving clinical and preclinical data supporting dual payload approaches and identify where the field is seeing meaningful therapeutic advantage